Authority Hacker Podcast
One Reporter’s Life-Altering Psychedelic Trip
Why It Matters
As psychedelics move from fringe to mainstream medical research, ibogaine represents a high‑risk, high‑reward option that could reshape treatment for addiction and trauma if safety concerns are addressed. The episode highlights both the promise of neuroplasticity‑based therapies and the real-world challenges patients face when seeking them outside the U.S., underscoring the urgency of policy and clinical research reforms.
Key Takeaways
- •Ibogaine shows potential for PTSD and addiction treatment.
- •Treatment requires extensive medical screening and supervised setting.
- •Costs exceed $8,000, with discounts for veterans.
- •Neuroplasticity activation may aid neurodegenerative diseases.
- •High cardiac risk demands continuous monitoring during sessions.
Pulse Analysis
In this Sunday Daily episode, veteran journalist Robert Draper shares his personal ibogaine journey, a psychedelic derived from the West African iboga shrub. Though illegal in the United States as a Schedule I substance, the drug has attracted attention from high‑profile figures such as Senator Kyrsten Sinema and former Texas governor Rick Perry, who cite its promise for treating PTSD, traumatic brain injury, and addiction. Draper’s candid recounting of a ten‑hour ceremony in a Mexican clinic highlights the growing curiosity among journalists and policymakers about alternatives to conventional psychiatric medication.
The conversation delves into the science behind ibogaine’s effects. Recent Stanford research on 30 combat veterans revealed increased theta‑wave activity and heightened neuroplasticity, suggesting the drug could reset neural pathways damaged by trauma or neurodegenerative disease. Early data also point to a modest reduction in brain‑age metrics—about 1.3 years per treatment—and potential benefits for conditions like Alzheimer’s, Parkinson’s, and ALS. However, the therapy carries significant cardiac risks, including arrhythmia, which necessitates continuous heart monitoring, IV nutrition, and a rigorous 36‑hour pre‑screening protocol. The cost remains steep, roughly $8,350 per course, though veterans and first responders may receive a $1,000 discount or grant assistance.
Draper’s story sits within a broader surge of psychedelic research reshaping mental‑health treatment and investment landscapes. Compounds such as ketamine, psilocybin, and MDMA are moving through clinical trials, challenging the traditional pharmaceutical paradigm and prompting regulatory reconsideration. For business leaders, the ibogaine narrative underscores emerging market opportunities in specialized clinics, tele‑health monitoring platforms, and biotech firms developing safer analogues. As policymakers grapple with scheduling reforms, investors watch closely for the next wave of evidence‑based psychedelic therapies that could redefine care for PTSD, addiction, and age‑related cognitive decline.
Episode Description
The first time Robert Draper heard about the psychedelic drug ibogaine, it was from an unlikely source: the retired U.S. senator Kyrsten Sinema. As a political reporter for The New York Times, Draper often talks to figures like Ms. Sinema. But on this occasion, he said, she wanted to tell him about how she had tried ibogaine, which is illegal in the United States. She’d become such a believer in the drug that she was pushing her home state of Arizona to fund clinical trials for veterans with combat-related trauma.
Draper found that Ms. Sinema wasn’t the only politician to take up the cause. Rick Perry, the former Texas governor, Republican presidential candidate and Trump energy secretary, has also advocated for research into ibogaine in recent years and taken the drug himself. In 2025, because of Mr. Perry’s efforts, Texas became the first state to dedicate public funds to ibogaine research with veterans.
Recent studies of ibogaine at Stanford University and elsewhere suggest that it might prove effective in treating post-traumatic stress disorder, traumatic brain injuries, addiction and a range of other conditions. As Draper reported on ibogaine’s transformative effects on others, he wondered: Could it help him, too?
Today, on “The Sunday Daily,” Natalie Kitroeff talks to Robert Draper about what drew him to travel to Mexico to try ibogaine, and how his trip changed his life.
On Today’s Episode:
Robert Draper (usually) writes about domestic politics for The New York Times.
Background Reading:
It’s an Obscure Psychedelic Used to Treat Trauma. Could It Help Me?
The Long, Strange Trip of Rick Perry
Art Credit: Illustration By Melissa Santamaría
Subscribe today at nytimes.com/podcasts or on Apple Podcasts and Spotify. You can also subscribe via your favorite podcast app here https://www.nytimes.com/activate-access/audio?source=podcatcher. For more podcasts and narrated articles, download The New York Times app at nytimes.com/app.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Comments
Want to join the conversation?
Loading comments...